# В. В. Бредер

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/a5016242437/

## Facts

| Field | Value |
| --- | --- |
| Citations | 21,821 |
| Field | Hepatocellular Carcinoma Treatment and Prognosis |
| h-index | 32 |
| i10-index | 53 |
| Last Known Institution | Russian Cancer Research Center NN Blokhin |
| OpenAlex ID | https://openalex.org/A5016242437 |
| ORCID iD | https://orcid.org/0000-0002-6244-4294 |
| Works | 241 |

## Researcher papers

- [Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial](https://scholariq.org/papers/lenvatinib-plus-pembrolizumab-versus-lenvatinib-plus-placebo-for-advanced/)
- [Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma](https://scholariq.org/papers/four-year-overall-survival-update-from-the-phase-iii-himalaya-study-of/)
- [Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase−Positive Non–Small Cell Lung Cancer](https://scholariq.org/papers/ensartinib-vs-crizotinib-for-patients-with-anaplastic-lymphoma-kinase-positive/)

## Researcher topics

- [Hepatocellular Carcinoma Treatment and Prognosis](https://scholariq.org/topics/hepatocellular-carcinoma-treatment-and-prognosis/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Liver Disease Diagnosis and Treatment](https://scholariq.org/topics/liver-disease-diagnosis-and-treatment/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)

## Researcher university

- [Russian Cancer Research Center NN Blokhin](https://scholariq.org/institutions/russian-cancer-research-center-nn-blokhin/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.